Consonance-Hfw Acq Corp (SRZN)

$13.75 +0.05 (0.33%)
Market Cap 117.84M
Revenue (ttm) 10.66M
Net Income (ttm) -63.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -596.25%
Debt to Equity Ratio 0.00
Volume 6,300
Avg Vol 20,230
Day's Range N/A - N/A
Shares Out 8.57M
Stochastic %K 48%
Beta 0.63
Analysts Strong Sell
Price Target $37.00

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat di...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 489 9000
Address:
171 Oyster Point Boulevard, Suite 400, South San Francisco, United States
Jessikah__Liu
Jessikah__Liu Oct. 25 at 7:55 PM
I like this. $EEIQ is def positioning for something and it could turn up to be the first 100% mover next week. Whatever their plans, it has great volatility and is a safe hold until well into next year. Thanks for bringing my attention to these others. I was watching the $SRZN action but completely missed $GTBP. And that one's a favorite of mine. Have you noticed the slow build $LBGJ has been making lately? That's a hard one to time but when it makes its move it's likely to be legendary.
0 · Reply
Jw242
Jw242 Oct. 22 at 4:04 PM
$SRZN of course the market shart when we get a little mojo
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 20 at 11:54 AM
$SRZN Surrozen was mentioned here:
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 18 at 7:30 AM
$SRZN now we know what's that second drug of Eyebio/Merck. Tiespectus blocks VEGF. So Merck is now developing one WNT drug and one VEGF drug. Not sure what's the difference between Tiespectus and Eylea.
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 17 at 5:54 PM
$SRZN Eyebio/Merck is advertising their drug at the Eyecelerator event which could also help us.
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 17 at 4:01 PM
$SRZN yes its over we will be bankrupt soon.
1 · Reply
Jw242
Jw242 Oct. 17 at 4:00 PM
$SRZN it’s over.
0 · Reply
Jw242
Jw242 Oct. 17 at 3:59 PM
$SRZN why won’t they manipulate this up? But always down w the sell walls
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 16 at 8:00 PM
$SRZN why do they need weeks to fill such a position? Are they just trolling or is it a real job? Can't imagine that its hard to find a scientist in San Francisco.
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 15 at 5:21 PM
$SRZN i was looking around on LinkedIn and saw that somebody from Abbvie liked a post from our new VP. Then i checked what Abbvie works on or worked on in ophthalmology and i found some interesting things. They got approval for a sustained release implant called Durysta. Because of the side effects it only got approval in the US but not Europe.
1 · Reply
Latest News on SRZN
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 4, 2025, 4:15 PM EDT - 7 weeks ago

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Surrozen to Present at Upcoming Healthcare Investor Conference

Sep 3, 2025, 4:15 PM EDT - 7 weeks ago

Surrozen to Present at Upcoming Healthcare Investor Conference

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 8, 2025, 4:05 PM EDT - 2 months ago

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025, 8:30 AM EDT - 5 months ago

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025, 4:05 PM EDT - 6 months ago

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 31, 2025, 4:05 PM EDT - 7 months ago

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Mar 24, 2025, 9:00 AM EDT - 7 months ago

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Surrozen to Present at Upcoming Healthcare Investor Conferences

Nov 6, 2024, 4:30 PM EST - 1 year ago

Surrozen to Present at Upcoming Healthcare Investor Conferences

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Nov 6, 2024, 9:00 AM EST - 1 year ago

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Nov 4, 2024, 8:30 AM EST - 1 year ago

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Jun 12, 2024, 8:30 AM EDT - 1 year ago

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 9, 2024, 8:30 AM EDT - 1 year ago

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Provides First Quarter 2024 Financial Results and Business Update

May 8, 2024, 4:05 PM EDT - 1 year ago

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Apr 3, 2024, 8:40 AM EDT - 1 year ago

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Apr 1, 2024, 8:30 AM EDT - 1 year ago

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Apr 1, 2024, 8:30 AM EDT - 1 year ago

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Surrozen Provides Corporate Update on Clinical Programs

Jan 18, 2024, 8:30 AM EST - 1 year ago

Surrozen Provides Corporate Update on Clinical Programs

Surrozen Provides Third Quarter 2023 Financial Results

Nov 8, 2023, 4:05 PM EST - 2 years ago

Surrozen Provides Third Quarter 2023 Financial Results

Surrozen Provides Second Quarter 2023 Financial Results

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Surrozen Provides Second Quarter 2023 Financial Results

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

Jun 5, 2023, 8:30 AM EDT - 2 years ago

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

May 10, 2023, 4:05 PM EDT - 2 years ago

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Apr 5, 2023, 8:30 AM EDT - 2 years ago

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript

Mar 25, 2023, 10:02 AM EDT - 2 years ago

Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Mar 22, 2023, 4:01 PM EDT - 2 years ago

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Mar 20, 2023, 4:30 PM EDT - 2 years ago

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Jan 4, 2023, 4:41 PM EST - 3 years ago

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 4:30 PM EST - 3 years ago

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Oct 10, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Surrozen Reports Second Quarter 2022 Financial Results

Aug 11, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports Second Quarter 2022 Financial Results

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Jun 13, 2022, 8:00 AM EDT - 3 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

May 24, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

May 18, 2022, 8:00 AM EDT - 3 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

May 16, 2022, 8:00 AM EDT - 3 years ago

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

Surrozen Reports First Quarter 2022 Financial Results

May 11, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports First Quarter 2022 Financial Results

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

May 5, 2022, 8:00 AM EDT - 3 years ago

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 2, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 24, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Jan 10, 2022, 8:00 AM EST - 4 years ago

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Jan 5, 2022, 8:00 AM EST - 4 years ago

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Surrozen Reports Third Quarter 2021 Financial Results

Nov 15, 2021, 4:00 PM EST - 4 years ago

Surrozen Reports Third Quarter 2021 Financial Results

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

Nov 5, 2021, 8:00 AM EDT - 4 years ago

Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference

Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action

Oct 6, 2021, 7:17 AM EDT - 4 years ago

Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical Action

Jessikah__Liu
Jessikah__Liu Oct. 25 at 7:55 PM
I like this. $EEIQ is def positioning for something and it could turn up to be the first 100% mover next week. Whatever their plans, it has great volatility and is a safe hold until well into next year. Thanks for bringing my attention to these others. I was watching the $SRZN action but completely missed $GTBP. And that one's a favorite of mine. Have you noticed the slow build $LBGJ has been making lately? That's a hard one to time but when it makes its move it's likely to be legendary.
0 · Reply
Jw242
Jw242 Oct. 22 at 4:04 PM
$SRZN of course the market shart when we get a little mojo
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 20 at 11:54 AM
$SRZN Surrozen was mentioned here:
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 18 at 7:30 AM
$SRZN now we know what's that second drug of Eyebio/Merck. Tiespectus blocks VEGF. So Merck is now developing one WNT drug and one VEGF drug. Not sure what's the difference between Tiespectus and Eylea.
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 17 at 5:54 PM
$SRZN Eyebio/Merck is advertising their drug at the Eyecelerator event which could also help us.
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 17 at 4:01 PM
$SRZN yes its over we will be bankrupt soon.
1 · Reply
Jw242
Jw242 Oct. 17 at 4:00 PM
$SRZN it’s over.
0 · Reply
Jw242
Jw242 Oct. 17 at 3:59 PM
$SRZN why won’t they manipulate this up? But always down w the sell walls
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 16 at 8:00 PM
$SRZN why do they need weeks to fill such a position? Are they just trolling or is it a real job? Can't imagine that its hard to find a scientist in San Francisco.
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 15 at 5:21 PM
$SRZN i was looking around on LinkedIn and saw that somebody from Abbvie liked a post from our new VP. Then i checked what Abbvie works on or worked on in ophthalmology and i found some interesting things. They got approval for a sustained release implant called Durysta. Because of the side effects it only got approval in the US but not Europe.
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 14 at 3:19 PM
$SRZN Eyecelerator conference is this week.
0 · Reply
raticals
raticals Oct. 13 at 4:06 PM
$SRZN this thing is a coiled spring bigtime
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 12 at 11:10 AM
$SRZN nearly impossible that Surrozen will not be acquired in this environment. Thinking about it even Merck could be interested to get more WNT drugs if they see good results in their trials already. They could get our combination drugs and they would destroy any potential competition if they buy the last WNT drug company that's working on eye diseases. https://hubs.li/Q03LHt8V0
1 · Reply
raticals
raticals Oct. 9 at 10:35 PM
$SRZN short interest creeping up again
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 9 at 7:13 PM
$SRZN some questions that i have are what happened to their sweets platform? Did they delete that after the liver drug failure? What are the scientists working on now? The ophthalmology drugs that we have on the pipeline are kinda done regarding preclinical development and will move into the clinic soon so the scientists must be working on something else since they didn't lay them off. Could they be working on the targeted protein degradation technology to make cancer drugs as mentioned in one release by Surrozen? That could be very interesting and that potential value isn't really visible to shareholders.
0 · Reply
raticals
raticals Oct. 9 at 4:01 PM
$SRZN took one for the team sold 10,000 shares at 14 to kickstart things
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 9 at 9:40 AM
$SRZN Merck added another clinical trial in ophthalmology with a drug acquired through the Eyebio acquisition. Not sure what exactly it is but probably another WNT drug.
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 8 at 7:45 AM
$SRZN an article about BI and Re-Vana.
1 · Reply
raticals
raticals Oct. 7 at 1:58 PM
$SRZN I would literally never asked for anything in my life again. All I ask, is that the stock does. $SPRB move. It seems like a simple request 😆
1 · Reply
raticals
raticals Oct. 7 at 12:46 AM
$SRZN this gonna pull an $SPRB soon?
1 · Reply
topstockalerts
topstockalerts Oct. 6 at 8:57 PM
After Hours Top Gainers PT2 $OSCX $PASW $BRTX $MGN $SRZN
0 · Reply
W1nTheM4rket
W1nTheM4rket Oct. 6 at 6:46 PM
$SRZN NXXT giving textbook strength. Loving this momentum
0 · Reply